CAR T drives acute myeloid leukemia into submission in pre-clinical studies
A chimeric antigen receptor (CAR) T-cell construct designed to overcome difficulties with prior attempts showed good efficacy against AML in mouse models.
Dr. Maus is the Paula J. O'Keeffe Endowed Chair of the Massachusetts General Hospital Cancer Center and the Director of the Cellular Immunotherapy Program. She is also a Professor of Hematology and Oncology at Massachusetts General Hospital and Harvard Medical School, where she runs a laboratory focused on developing and improving CAR T cell therapy for cancer patients while also periodically attending for the bone marrow transplant service. Dr. Maus grew up in New York, NY and attended Massachusetts Institute of Technology for her undergraduate degree in Biology and Literature. She then earned her MD, PhD from the University of Pennsylvania School of Medicine under the direction of her PhD mentor, Dr. Carl June. She then did a one-year postdoctoral fellowship with Dr. Kathy High at the Children’s Hospital of Philadelphia, completed her clinical training in internal medicine, hematology, and oncology as a resident at the University of Pennsylvania Health System, and was a fellow at Memorial Sloan Kettering Cancer Center in Dr. Michel Sadelain’s lab.
Following her extensive training, Marcela returned to the University of Pennsylvania in 2012 to expand research efforts in the development of CAR T cells for lymphoma, myeloma, and other cancers. While there, Marcela continued her efforts on the preclinical development of CAR T cells and correlative studies of CAR T cell-related toxicities and resistance to therapies. Now, Dr. Maus runs a laboratory focused on developing and improving CAR T cell therapy for cancer patients. She has won numerous awards for her transformative research and is achieving her goal of using science to determine the best way to treat patients by harnessing the power of the immune system to solve intractable problems like cancer. She also enjoys training clinicians and scientists and watching her mentees succeed and become independent scientists and collaborators. Marcela is also a mother to three children, one large dog and one gecko. In her free time, Marcela enjoys spending time with her husband, kids, and pets, gardening, and skiing.
Departments, Centers, & Programs:
Treats:
Languages:
Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-724-1124
Medical Education
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
The Adolescent and Young Adult Cancer Program was created to optimize the care, outcomes, and experiences of adolescent and young adult patients.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
A chimeric antigen receptor (CAR) T-cell construct designed to overcome difficulties with prior attempts showed good efficacy against AML in mouse models.
Researchers at Massachusetts General Hospital (MGH) have discovered that the interferon gamma receptor (IFNgR) signaling pathway is critical for susceptibility of glioblastoma tumors to killing by CAR T-cell immunotherapy.
A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.
Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.
It’s fitting that the investigators who developed a new CAR T-based treatment for glioblastoma called their treatment platform “CAR-TEAM” cells, as it took a true team effort to bring their concept from the lab to the clinic.
Learn more about the findings and importance of a study led by a research and clinical team from the Mass General Cancer Center who is developing new cell therapy for patients with recurrent glioblastoma.
A chimeric antigen receptor (CAR) T-cell construct designed to overcome difficulties with prior attempts showed good efficacy against AML in mouse models.
Researchers at Massachusetts General Hospital (MGH) have discovered that the interferon gamma receptor (IFNgR) signaling pathway is critical for susceptibility of glioblastoma tumors to killing by CAR T-cell immunotherapy.
A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.
Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.